Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of FDA-approved prescription medications originally developed for type 2 diabetes management. These medications work by mimicking the GLP-1 hormone, which helps regulate blood sugar levels, slows gastric emptying, and reduces appetite. Popular GLP-1 medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda).
Clinical trials have demonstrated significant weight loss results, with patients losing an average of 15-22% of their body weight with semaglutide and tirzepatide, along with significant improvements in cardiovascular health, blood pressure, and metabolic markers.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Connect with board-certified physicians licensed in your state from the comfort of your home. No waiting rooms, no commute.
Access semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — all FDA-approved.
Every prescription is evaluated and issued by a US-licensed, board-certified physician specializing in metabolic and obesity medicine.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state below to find local GLP-1 telehealth providers and start your online consultation.
Get prescribed GLP-1 medications online in the largest US cities. Licensed physicians available in your city.
Our streamlined process connects you with licensed physicians who can prescribe GLP-1 medications in just a few simple steps.
Complete a brief, secure medical questionnaire. Our providers will review your health history, current medications, and BMI to determine your eligibility for GLP-1 therapy.
A board-certified physician licensed in your state conducts a personalized telehealth consultation. They will discuss treatment options, potential side effects, and create a personalized plan.
If approved, your GLP-1 medication ships directly to your door from a licensed US pharmacy, typically within 3-5 business days in temperature-controlled packaging.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 receptor agonists are FDA-approved prescription medications that help manage weight and blood sugar levels. They include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda). They work by reducing appetite, slowing digestion, and improving insulin regulation.
Yes. Licensed telehealth providers can prescribe GLP-1 medications online after a full medical consultation. You will need to complete a health assessment and consult with a board-certified physician who will evaluate whether GLP-1 treatment is appropriate for your individual needs.
Clinical trials show average weight loss of 15% of body weight with semaglutide and up to 22% with tirzepatide over 72 weeks of treatment. Individual results vary based on factors like dosage, lifestyle, and health profile.
Many insurance plans cover GLP-1 medications when prescribed for FDA-approved indications. Coverage varies by plan and specific medication. Manufacturer savings programs and coupon options can significantly reduce out-of-pocket costs.
GLP-1 medications are FDA-approved with extensive safety data from clinical trials. Common side effects include nausea and digestive discomfort, which typically improve over time. Your healthcare provider will evaluate your individual health profile to ensure safe use.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
